Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2020-06-18 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
公司章程
Governance Information Classification · 100% confidence The document is a detailed company charter or articles of association (章程) for Beijing Sinocelltech Group Limited, including chapters on general provisions, business scope, share issuance, shareholders and shareholders' meetings, board of directors, senior management, supervisory board, financial accounting system, profit distribution, audit, and other corporate governance matters. It references the company law, securities law, and regulatory bodies like the China Securities Regulatory Commission and Shanghai Stock Exchange. The content is about the internal rules, governance structure, shareholder rights, meeting procedures, and corporate organization. It is not a financial report, earnings release, or announcement but a governance document outlining the company's bylaws and governance practices. Therefore, it fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance provisions, not just an announcement or summary.
2020-06-18 Chinese
首次公开发行股票科创板上市公告书
Regulatory Filings Classification · 95% confidence The document is titled as a "上市公告书" which translates to "Listing Announcement" or "IPO Listing Announcement" for Beijing Sinocelltech Group Limited. It contains detailed information about the company's risks, financial status, product development, and market competition related to its initial public offering (IPO) on the Shanghai Stock Exchange's STAR Market (科创板). The document discusses the company's business, financial losses, risks, and the stock listing date (June 22, 2020). It is not a financial report like an annual or quarterly report, nor is it a simple announcement of a report. It is a formal regulatory filing announcing the company's IPO listing and related disclosures. This type of document fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories. The document is lengthy (15,000 characters) and contains substantive information, not just a brief announcement or certification. Therefore, the classification is RNS with high confidence.
2020-06-18 Chinese
首次公开发行股票并在科创板上市发行结果公告
Capital/Financing Update Classification · 100% confidence The document is titled as an "发行结果公告" which translates to "Issuance Results Announcement" for the company's initial public offering (IPO) and listing on the STAR Market (科创板). It details the results of the stock issuance, including subscription statistics, allocation to strategic investors, online and offline subscription results, and the lottery results for offline allotment. The document includes detailed share allocation numbers, subscription amounts, and lock-up periods. It is a formal announcement of the outcome of a capital raising event (IPO). There is no indication that this is a full financial report, audit, or management discussion. It is not a regulatory filing or a report publication announcement but a detailed update on the capital issuance results. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2020-06-14 Chinese
首次公开发行股票并在科创板上市招股说明书
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus (招股说明书) for an initial public offering (IPO) on the Shanghai Stock Exchange STAR Market (科创板). It includes extensive information about the company's business, financial status, product pipeline, risks, and market competition. The document contains detailed financial data, business descriptions, and risk disclosures typical of an IPO prospectus. This type of document is not an earnings release, annual report, or other routine financial report but a comprehensive offering document for new stock issuance. According to the filing definitions, this corresponds to a Capital/Financing Update (CAP) as it relates to fundraising and issuance of new shares. The document is not a simple announcement or a regulatory filing but a full prospectus with substantive content. Therefore, the correct classification is CAP with high confidence.
2020-06-14 Chinese
首次公开发行股票并在科创板上市网下初步配售结果及网上中签结果公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) of Beijing Shenzhou Cell Biotechnology Group Co., Ltd., including the offline preliminary allotment results and online lottery results for the stock issuance on the STAR Market (科创板). It contains detailed information about the strategic placement, offline and online subscription, allotment numbers, subscription prices, payment instructions, and the lottery process for the IPO shares. The document is not a financial report like an annual or quarterly report, nor is it a transcript, audit report, or management report. It is a formal announcement of the results of the IPO allotment and subscription process, which fits the category of a Capital/Financing Update (CAP) as it relates to the company's fundraising and issuance of new shares. The document length is substantial and contains detailed allotment data, not just a brief notice or a report publication announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-06-10 Chinese
首次公开发行股票并在科创板上市网上发行申购情况及中签率公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the initial public offering (IPO) of Beijing Shenzhou Cell Biotechnology Group Co., Ltd., detailing the subscription situation, allocation results, and lottery draw for the online issuance of shares on the STAR Market. It includes information about the underwriting, subscription rates, allocation mechanisms, and payment instructions. The document is not a full financial report, audit, or management discussion but rather a formal announcement of the subscription and allocation results related to the IPO process. It does not contain financial statements or detailed financial analysis but focuses on the issuance and subscription process and results. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities such as IPOs.
2020-06-09 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.